| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| R&D Expense | $396.4M | -6.5% |
| SG&A Expense | $105.4M | +2.0% |
| Operating Income | -$487.3M | -147.8% |
| Income Tax | $68K | +126.7% |
| Net Income | -$422.8M | -191.1% |
| EPS (Basic) | -$2.57 | -142.5% |
| EPS (Diluted) | -$2.57 | -142.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $175.0M | +37.6% |
| Short-term Investments | $657.4M | -27.6% |
| Accounts Receivable | $2.2M | -36.5% |
| Current Assets | $864.4M | -18.8% |
| Total Assets | $1.37B | +19.1% |
| Current Liabilities | $102.2M | +31.1% |
| Total Liabilities | $144.5M | +17.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$347.7M | +2.9% |
| Capital Expenditures | $15.9M | +23.0% |
| Investing Cash Flow | -$88.8M | -135.6% |
| Financing Cash Flow | $484.3M | +2617.8% |
| Free Cash Flow | -$363.6M | +2.0% |
| Stockholders' Equity |
| $1.23B |
| +19.3% |